ABSTRACT
The survival of patients with myeloma ranges from under a year to over 10 years. This heterogeneity relates to specific characteristics both of the tumour itself and of the host. The identification of factors influencing prognosis is of major importance in order to predict outcome, to guide the choice of therapy, and to enrol homogeneous series of patients in clinical trials.
